Three weeks left! The 2026 Frost & Sullivan Summit – Agenda for the Healthcare & Life Sciences New Investment Forum announced

The Frost & Sullivan Growth, Innovation and Leadership Best Practices Award (referred to as GIL Award) aims to recognize outstanding companies that have made significant contributions and achieved leadership positions in various industries. After nearly 30 years of development worldwide, the authority and fairness of this award have been widely recognized by the investment and financial communities as well as industry experts. To date, over 5,000 excellent companies have been honored globally.

2026 marks the 65th anniversary of Frost & Sullivan globally.Frost & Sullivan ChinaFrost & Sullivan China will continue to track and study numerous entrepreneurial and investment success cases in high-tech and strategic emerging industries within China during 2026. It will conduct objective analysis and comprehensive evaluation of the innovation capabilities, business models, founding teams, technical abilities, and future prospects of participating companies. Together with a professional review committee, several outstanding biotech leadership companies will be selected. The winners of the 2026 GIL Award will be announced during this conference at the 65th anniversary celebration of Frost & Sullivan globally and the 20th anniversary celebration of Frost & Sullivan Summit in China.

At this conference, Frost & Sullivan will release seven blue books coveringHK 18A, biopharmaceutical overseas expansion, gene therapy, brain-computer interface, digital medical imaging, AI healthcare, and synthetic biology. These books focus on the forefront of global technological changes and industrial restructuring, providing deep insights into innovation trends and investment directions in the life and health sector.

English and Chinese version of the '2026 HK 18A Biotech Industry Development Blue Book'

With the acceleration of innovation drug research and development, the continuous improvement of Hong Kong Stock Exchange's capital market systems, and multiple factors in the transformation and upgrading of China's biopharmaceutical industry, the HK 18A rules have gone through pilot trials and now enter a mature development phase of standardization and normalization. The reform of China's biopharmaceutical capital market has been fully implemented. As a special listing channel for unprofitable biotech companies, the 18A system breaks down the barriers between innovation research and development and the capital market, helping domestic pharmaceutical companies achieve full chain breakthroughs from clinical development to industrialization.

Under this background, Frost & Sullivan integrates vast data from the global biotech secondary market, investment and financing in both primary and secondary markets, and IPO issuance transactions to compile this blue book. It reviews the ten-year cycle changes in the global biopharmaceutical capital market and the evolution path of 18A policies vertically, and dissects the 18A industry landscape, popular innovation tracks, and core fundamentals of listed companies horizontally. It quantifies valuation and operating data throughout the entire process from Pre-IPO financing, new share issuance to post-Listing secondary market performance, and combines Hong KongRWAthe innovation of asset tokenization to explore diverse financing models for biopharmaceuticals, and includes authoritative lists such as annual IPO intermediaries, listed companies, and institutional investments. It deeply analyzes the growth prospects, pipeline value, and commercialization potential of each niche track, providing quantitative data, industry insights, and decision-making basis for biopharmaceutical companies, primary and secondary investors, capital market intermediaries, and industry regulators.

English and Chinese version of the '2026 China Biopharmaceutical Internationalization Development Blue Book'

For Chinese biopharmaceutical companies, going global is an inevitable choice after completing early capacity accumulation, to actively participate in global industrial division of labor and seek larger market space and higher value realization paths. In the past, Chinese biopharmaceutical companies relied more on local clinical resources, engineer advantages, and rapid iteration capabilities to start innovation. However, as local competition intensifies, payment constraints increase, and similar pipelines multiply, internationalization becomes an important direction for companies to break through growth boundaries, verify innovation value, and enhance capital recognition. Meanwhile, global pharmaceutical companies are re-evaluating Chinese innovation capabilities, considering Chinese companies as important research cooperation partners, asset sources, and industrial chain partners. Based on this, Frost & Sullivan releases the '2026 China Biopharmaceutical Internationalization Development Blue Book' to systematically analyze the stage characteristics, driving factors, main paths, and future trends of internationalization development of Chinese biopharmaceutical companies, and discuss the long-term value and development blueprint of the Chinese biopharmaceutical industry in the global market with industry participants, investors, and stakeholders.

English and Chinese version of the '2026 Global Gene Therapy Industry Development Blue Book'

Driven by continuous technological breakthroughs, improved regulatory frameworks, and capital investment, the gene therapy industry is accelerating from the early technical exploration stage to commercialization. Notably, China's '15th Five-Year Plan' has included bio-manufacturing as one of the core directions of strategic emerging industries, and gene therapy is identified as a key area requiring 'key progress'. Under the '15th Five-Year' macro-strategy, gene therapy is no longer just a market behavior driven by technical exploration and capital, but has become a crucial component of national bi-economic competitiveness, requiring systematic improvements in vector technology, production process upgrades, clinical conversion efficiency, and regulatory system perfection. However, the industry still faces systemic challenges such as complex production processes, insufficient large-scale production capacity, high shell rate and cost pressure, lack of long-term data validation, and imperfect payment system. In this context, Frost & Sullivan aims to provide forward-looking market insights and strategic decision-making references for the development stage, technical system, and industrial chain structure of the gene therapy industry, as well as analyze key process barriers, commercialization paths, and market space, offering insights for all parties in the industry.

English and Chinese version of the '2026 Global Brain-Computer Interface Industry Development White Paper'

Currently, innovative achievements in the field of brain-computer interfaces in China are emerging continuously, and the industry is developing rapidly, becoming an important area for the deep integration of technological innovation and industrial innovation. By establishing a full-chain ecosystem of 'technical innovation—application in scenarios—industrial clustering' and prioritizing review mechanisms, China is accelerating its transition from key technical breakthroughs to global industry leadership, creating new advantages for Chinese enterprises in international competition. In this context, Frost & Sullivan aims to provide forward-looking market insights and strategic decision-making references for all parties in the industry chain by analyzing the development stage, structural features, and evolution path of the industry, as well as the current situation and market space of key application areas.

English and Chinese version of the '2026 Global Digital Medical Imaging Ecosystem Industry Development Blue Book'

As artificial intelligence reshapes various industries at an unprecedented speed, the healthcare sector is undergoing a profound transformation from "experience-driven" to "data intelligence". In this transformation, AI medical imaging is undoubtedly one of the most highly focused and clinically valuable sectors. However, this integration is triggering deeper qualitative changes: AI is no longer just the "second pair of eyes" of radiologists, but a decisive factor in the digital evolution of the medical imaging ecosystem. Starting from the current construction and pain points of the medical imaging ecosystem, we will analyze how AGI can empower the medical imaging ecosystem, and then look ahead to the future development of the digital medical imaging ecosystem. Through this blue book, we hope to help the public better understand the development of the medical imaging ecosystem, and how AI medical imaging can truly become a partner and digital twin in doctors' diagnosis and treatment processes.

English and Chinese version of the '2026 Global AI Healthcare Industry Development Blue Book'

In recent years, with the continuous development of new-generation information technologies such as big data, cloud computing, and the Internet of Things, especially the breakthroughs in generative artificial intelligence and large model technologies, artificial intelligence (AI) has entered a stage of accelerated application worldwide. The healthcare industry, as a data-intensive and highly professional field, is becoming an important scenario for deep integration of artificial intelligence. AI is making technological progress in areas such as medical imaging, auxiliary diagnosis, disease management, drug research and development, and hospital operation management, promoting the upgrade of the healthcare service system towards intelligence and precision.

Driven by multiple factors including policy support, technological maturity, and capital attention, China's AI healthcare industry is in a critical period of transitioning from technical verification to large-scale implementation. Industrial chain collaboration continues to deepen, niche tracks accelerate evolution, and the industry competition pattern becomes clearer. How to seize development opportunities during the restructuring of the industrial structure and upgrading of technical paths has become a core issue for industry participants.

English and Chinese version of the '2026 Global Synthetic Biology Industry Development White Paper'

Synthetic biology is widely defined by academia and industry as the third life science revolution following the discovery of the DNA double helix structure and the genome technology revolution. The 2026 Government Work Report clearly states the need to cultivate and strengthen emerging and future industries, and promote bio-manufacturing as a new economic growth point. Synthetic biology and bio-manufacturing are no longer just technical issues, but a triple intersection of national security (supply chain autonomy and control), climate agenda (Dual Carbon/Zero-carbon Negative Carbon), and economic increment (new quality productive forces). Based on long-term insights into global cutting-edge technology and bio-manufacturing industry, Frost & Sullivan launches the '2026 Global Synthetic Biology Industry Development Blue Book', using a comprehensive industrial chain map, country/region comparison, and triple lens of regulation-technology-business to deeply understand industry development trends, providing a global perspective for industry professionals.

Life Science New Investment Forum

Event Consultation | Sponsorship Cooperation | Attendance Consultation

📞 Conference Consultation Hotline:

021-3209-6800 ext. 8672

📧 Conference Consultation Email:

gil@frostchina.com